FindTrial
Sign In

SBT6050

DRUG2 trials

Sponsors

Silverback Therapeutics

Conditions

HER2 Positive Solid TumorsHER2-expressing Non-small Cell Lung CancerHER2-positive Breast CancerHER2-positive Colorectal CancerHER2-positive Gastric Cancer

Phase 1

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
NCT04460456
Silverback TherapeuticsHER2 Positive Solid Tumors
Start: 2020-07-27End: 2022-12-31Updated: 2022-06-30
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
TerminatedNCT05091528
Silverback TherapeuticsHER2-expressing Non-small Cell Lung Cancer, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer +1
Start: 2022-02-08End: 2022-07-07Updated: 2022-08-18

Related Papers

393 A phase 1/2 study of SBT6050 combined with trastuzumab deruxtecan (T-DXd) or trastuzumab and tucatinib with or without capecitabine in patients with HER2-expressing or HER2-amplified cancers
Regular and Young Investigator Award Abstracts2021-11-016 citations
317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors
Regular and Young Investigator Award Abstracts2020-11-0113 citations